Taxus Has Lower MACE Rate Than Cypher, American Journal of Cardiology Study
Angiotech Pharmaceuticals, Inc corporate partner, Boston Scientific ("BSC"), today welcomed the results of an independent study demonstrating that BSC's TAXUS(R) Express2(TM) paclitaxel- eluting stent system had lower incidents of major adverse cardiac events (MACE) than Johnson & Johnson's Cypher(R) sirolimus-eluting stent system. The results of the study were published in the August 1 edition of the American Journal of Cardiology.
(I-Newswire) - The study showed a safety trend in favor of TAXUS over Cypher in the cumulative one-year MACE rate, the study's primary endpoint, which was 15.6 percent for TAXUS versus 20.4 percent for Cypher. Of the three MACE components, the results favored TAXUS over Cypher in the cumulative rates of target vessel revascularization ( TVR, or retreatment rate ) ( 5.9 percent for TAXUS versus 10.3 percent for Cypher ) and myocardial infarction ( 10 percent for TAXUS versus 14.1 percent for Cypher ). For the third MACE component, cumulative mortality, the results were essentially equivalent ( 7.2 percent for TAXUS versus 7.7 percent for Cypher ).
"The major finding of this study is that unrestricted use of PESs ( paclitaxel-eluting stents ) in a universal drug-eluting stent environment is associated with a nonsignificantly lower incidence of major adverse cardiac events at one year compared with SESs ( sirolimus-eluting stents )," according to the study.
"We are pleased that this new study reconfirms the strong safety profile of paclitaxel-eluting stent systems we have seen across our broad range of clinical trials as well as in approximately 1.5 million TAXUS systems implanted to date," said Hank Kucheman, President of BSC's Interventional Cardiology business. "It is particularly impressive that the safety results demonstrated a trend in favor of the paclitaxel-eluting system among the challenging diabetic patient population in this study. Our focus on safety is one of the reasons TAXUS is the worldwide market leader in drug- eluting stents."
The study, conducted at the Rotterdam Cardiology Hospital in The Netherlands, included 293 patients with diabetes and de novo coronary artery disease who were enrolled in identical sequential registries, one assessing the paclitaxel-eluting stents and one assessing the sirolimus-eluting stents. BSC acquired worldwide exclusive rights from Angiotech to use paclitaxel to coat its coronary stent products and has co-exclusive rights to other vascular and non-vascular products.
Vancouver-based Angiotech Pharmaceuticals, Inc. is a specialty pharmaceutical company pioneering the combination of pharmaceutical compounds with medical devices and biomaterials to both create novel solutions for poorly addressed disease states and dramatically improve surgical outcomes. To find out more about Angiotech Pharmaceuticals, Inc. ( NASDAQ: ANPI, TSX: ANP ), please visit our website at angiotech.com.
Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words "anticipates," "believes," "may," "continue," "estimate," "expects," "may" and "will" and words of similar import, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, both nationally and in the regions in which the Company operates; technology changes; competition; changes in business strategy or development plans; the ability to attract and retain qualified personnel; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; liability and other claims asserted against the Company; and other factors referenced in the Company's filings with the United States Securities and Exchange Commission or the Canadian securities regulators. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company does not assume the obligation to update any forward-looking statements.
If you have questions regarding information in this press release contact the company listed below. I-Newswire.com is a press release service and not the author of this press release. The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies / PR Agencies submit their press releases once per week/month or quarter, make sure check the official company website for accurate release dates as our site displays the I-Newswire.com distribution date only. We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for inaccuracies or omissions in that information or for actions taken in reliance on that information.
Immerse yourself in mystery and magic with two exciting new casual games from Focus Multimedia and Big Fish Games Studios, one of the world’s leading casual game developers. Hidden Expedition Titanic and Azada join Focus’ popular Revival range of super-budget price games and are available in a store near you.
Edraw Max enables students, teachers and business professionals to reliably create and publish kinds of diagrams to represent any ideas. With large pre-drawn libraries and more than 4600 vector symbols, drawing couldn't be easier!
New range of cards launched to make you the cover star.Hallmark Cards in partnership with OK Magazine has launched an exclusive and exciting new range of greeting cards that gives people the chance to give family and friends the A-List treatment.
Many people choose not to pursue an accident claim. The reasons range from knowing the insurance company will settle; to they don't want the legal hassles and expense.
Many individuals and businesses have always purchased their personal computers from a well-known provider to pre-conceived specifications. Increasingly...
The effectiveness of SEO and PPC Services are directly related to the quality and quantity of the performance data that they have to work with. If you are seeking assistance in achieving a higher ranking on search engine results, then we suggest you visit RankYourWebsites.com, specialist in this area. If you have found your attempts at optimization to prove fruitless, the representatives at RankYourWebsites.com will have a solution to increase your traffic.
http://www.vineyardsforsalein.com/ - online island vineyard for sale, vineyard for sale paso, texas vineyard for sale, washington vineyard for sale, tuscany vineyard for sale, vineyard for sale santa, vineyard for sale California
Mark Flanagan, Managing Director of Manchester health and safety, food safety and fire safety consultancy, Shieldyourself, discussed the Scores on the Doors scheme when he made a guest appearance on the BBC’s 5 Live Radio Show recently.
